TAM
BTAI icon

Tocqueville Asset Management’s BioXcel Therapeutics BTAI Stock Holding History

Tocqueville Asset Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-738
Closed -$4.41K – 519
2024
Q4 		$4.41K Sell
738
-6
-0.8% -$50 ﹤0.01% 538
2024
Q3 		$7.26K Sell
744
-1,990
-73% -$26.7K ﹤0.01% 528
2024
Q2 		$56K Sell
2,734
-282
-9% -$9.44K ﹤0.01% 521
2024
Q1 		$136K Sell
3,016
-125
-4% -$5.96K ﹤0.01% 521
2023
Q4 		$148K Buy
3,141
+666
+27% +$37K ﹤0.01% 500
2023
Q3 		$100K Hold
2,475
– – ﹤0.01% 496
2023
Q2 		$264K Buy
2,475
+162
+7% +$53.9K ﹤0.01% 467
2023
Q1 		$690K Sell
2,313
-150
-6% -$64.1K 0.01% 383
2022
Q4 		$846K Buy
2,463
+672
+38% +$162K 0.02% 397
2022
Q3 		$339K Sell
1,791
-175
-9% -$40.6K 0.01% 495
2022
Q2 		$415K Buy
1,966
+797
+68% +$168K 0.01% 523
2022
Q1 		$391K Buy
1,169
+81
+7% +$23.5K 0.01% 565
2021
Q4 		$354K Sell
1,088
-50
-4% -$21.5K ﹤0.01% 615
2021
Q3 		$552K Sell
1,138
-93
-8% -$40.9K 0.01% 517
2021
Q2 		$572K Buy
1,231
+322
+35% +$176K 0.01% 525
2021
Q1 		$628K Buy
909
+590
+185% +$475K 0.01% 515
2020
Q4 		$236K Buy
319
+25
+9% +$19.5K ﹤0.01% 656
2020
Q3 		$204K Buy
+294
New +$221K ﹤0.01% 627

Other funds holding BTAI

M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Tocqueville Asset Management's BTAI Position: Q1 2025 in Review

Tocqueville Asset Management sold out of BioXcel Therapeutics (BTAI) in Q1 2025, closing a stake of 738 shares — an estimated $4.41K sold.

Tocqueville Asset Management first reported a position in BTAI in Q3 2020 and held it in 18 quarters. The position peaked at $846K in Q4 2022. 31 funds tracked by Wall St. Rank hold BTAI as of Q1 2025.

  • Tocqueville Asset Management reported no remaining BioXcel Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Tocqueville Asset Management sold 738 BioXcel Therapeutics shares in Q1 2025, an estimated $4.41K.
  • Tocqueville Asset Management first reported a position in BioXcel Therapeutics in Q3 2020 and held it in 18 quarters.
  • Tocqueville Asset Management's BioXcel Therapeutics position peaked at $846K in Q4 2022.
  • 31 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2025.

Based on Tocqueville Asset Management's 13F filing for Q1 2025, filed 13 May 2025.